Jordheim et al. identified F06/NERI02 (NSC130813) through in silico screening, as a small molecule inhibitor targeting ERCC1-XPF heterodimerization and demonstrated modest affinity for XPF and sensitized cancer cells to MMC and cisplatin (Figure 12) (200). Here, ERCC4 is linked to cancer.